BioXcel Therapeutics Inc. said FDA has granted Orphan Drug Designation for BXCL701, an investigational orally-available systemic innate immunity activator with dual mechanisms of action, for the treatment of acute myeloid leukemia.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
